Pfizer/Boehringer Spiriva For COPD Maintenance Therapy Approved By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating strong demand for the inhalation therapy, Pfizer and Boehringer are delaying launch until mid-year to ensure sufficient initial supplies of tiotropium bromide.